ALTIMMUNE, INC. (ALT) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -100.22M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 68.22M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-100.22M | (m) | (m) | $68.22M | (m) | (m) |
| 2026-03-31 | $-96.92M | (m) | (m) | $66.80M | (m) | (m) |
| 2025-12-31 | $-94.49M | $41.00K | (m) | $66.43M | (m) | -230460.98% |
| 2025-09-30 | $-90.46M | $20.00K | (m) | $67.80M | (m) | -452310.00% |
| 2025-06-30 | $-94.37M | $20.00K | (m) | $72.65M | (m) | -471850.00% |
| 2025-03-31 | $-98.19M | $20.00K | (m) | $76.57M | (m) | -490965.00% |
| 2024-12-31 | $-103.17M | $20.00K | (m) | $82.23M | (m) | -515860.00% |
| 2024-09-30 | $-111.93M | $52.00K | (m) | $79.35M | (m) | -215248.08% |
| 2024-06-30 | $-109.70M | $409.00K | (m) | $77.94M | (m) | -26822.00% |
| 2024-03-31 | $-100.96M | $410.00K | (m) | $70.04M | (m) | -24625.37% |
| 2023-12-31 | $-95.93M | $426.00K | (m) | $65.80M | (m) | -22518.54% |
| 2023-09-30 | $-85.40M | $279.00K | (m) | $68.07M | (m) | -30609.32% |
| 2023-06-30 | $-87.61M | $-81.00K | (m) | $69.94M | (m) | 108162.96% |
| 2023-03-31 | $-90.00M | $-79.00K | (m) | $72.68M | (m) | 113924.05% |
| 2022-12-31 | $-87.74M | $-68.00K | (m) | $70.54M | (m) | 129029.41% |
| 2022-09-30 | $-88.63M | $3.32M | (m) | $71.54M | (m) | -2670.13% |
| 2022-06-30 | $-97.08M | $3.48M | (m) | $80.49M | (m) | -2793.47% |
| 2022-03-31 | $-101.55M | $3.60M | (m) | $77.77M | (m) | -2817.48% |
| 2021-12-31 | $-96.91M | $4.41M | (m) | $74.54M | (m) | -2197.42% |
| 2021-09-30 | $-83.68M | $3.45M | (m) | $63.31M | (m) | -2428.72% |
| 2021-06-30 | $-68.80M | $6.23M | (m) | $51.14M | (m) | -1105.06% |
| 2021-03-31 | $-62.35M | $6.81M | (m) | $54.46M | (m) | -915.64% |
| 2020-12-31 | $-54.80M | $8.19M | (m) | $49.77M | (m) | -669.50% |
| 2020-09-30 | $-48.36M | $6.45M | (m) | $43.70M | (m) | -750.00% |
| 2020-06-30 | $-41.31M | $4.15M | (m) | $35.38M | (m) | -994.44% |
| 2020-03-31 | $-26.44M | $5.06M | (m) | $21.74M | (m) | -522.75% |
| 2019-12-31 | $-21.46M | $5.80M | (m) | $17.77M | (m) | -370.00% |
| 2019-09-30 | $-44.50M | $7.81M | (m) | $17.96M | (m) | -569.46% |
| 2019-06-30 | $-37.28M | $9.80M | (m) | $13.96M | (m) | -380.26% |
| 2019-03-31 | $-39.17M | $10.60M | (m) | $15.93M | (m) | -369.66% |
| 2018-12-31 | $-42.83M | $10.33M | (m) | $18.46M | (m) | -414.61% |
| 2018-09-30 | $-28.05M | $10.55M | (m) | $19.85M | (m) | -265.87% |
| 2018-06-30 | $-54.95M | $12.51M | (m) | $21.03M | (m) | -439.27% |
| 2018-03-31 | $-53.52M | $13.13M | (m) | $21.37M | (m) | -407.65% |
| 2017-12-31 | $-52.05M | $10.74M | (m) | $18.41M | (m) | -484.67% |
| 2017-09-30 | $-42.75M | (m) | (m) | $13.94M | (m) | (m) |
| 2017-06-30 | $-16.59M | (m) | (m) | $10.43M | (m) | (m) |
| 2017-03-31 | $-13.19M | (m) | (m) | $4.53M | (m) | (m) |
| 2016-12-31 | $-11.26M | (m) | (m) | $4.84M | (m) | (m) |
| 2016-09-30 | $-6.69M | (m) | (m) | $4.58M | (m) | (m) |
| 2016-06-30 | $-4.36M | (m) | (m) | $4.47M | (m) | (m) |
| 2016-03-31 | $-5.82M | (m) | (m) | $4.55M | (m) | (m) |
| 2015-12-31 | $-3.40M | (m) | (m) | $5.13M | (m) | (m) |
| 2015-09-30 | $-5.09M | (m) | (m) | $5.75M | (m) | (m) |
| 2015-06-30 | $-7.42M | (m) | (m) | $6.36M | (m) | (m) |
| 2015-03-31 | $-6.63M | (m) | (m) | $7.51M | (m) | (m) |
| 2014-12-31 | $-10.19M | (m) | (m) | $9.32M | (m) | (m) |
| 2014-09-30 | $-12.64M | (m) | (m) | $11.63M | (m) | (m) |
| 2014-06-30 | $-11.84M | (m) | (m) | $12.45M | (m) | (m) |
| 2014-03-31 | $-12.15M | (m) | (m) | $13.48M | (m) | (m) |
| 2013-12-31 | $-10.84M | (m) | (m) | $15.29M | (m) | (m) |
| 2013-09-30 | $-7.20M | (m) | (m) | $15.94M | (m) | (m) |
| 2013-06-30 | $-5.79M | (m) | (m) | $18.52M | (m) | (m) |
| 2013-03-31 | $-5.77M | (m) | (m) | $20.04M | (m) | (m) |
| 2012-12-31 | $-6.27M | (m) | (m) | $19.51M | (m) | (m) |
| 2012-09-30 | $-5.92M | (m) | (m) | $19.29M | (m) | (m) |
| 2012-06-30 | $-7.15M | (m) | (m) | $19.04M | (m) | (m) |
| 2012-03-31 | $-8.78M | (m) | (m) | $20.10M | (m) | (m) |
| 2011-12-31 | $-11.73M | $24.27M | (m) | $21.22M | (m) | -48.32% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-23.55M | $20.99M | (m) | $20.88M | (m) | -112.19% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |